The investigational monoclonal antibody amatuximab , has been granted orphan drug designation for the treatment of malignant mesothelioma by the European Commission.
The investigational monoclonal antibody amatuximab , has been granted orphan drug designation for the treatment of malignant mesothelioma by the European Commission.